沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片、呋塞米注射液治疗慢性心力衰竭患者的效果  

Effects of Sacubitril Valsartan sodium tablets combined with Metoprolol succinate sustained-release tablets and Furosemide injection in treatment of patients with chronic heart failure

作　　者：齐艳艳 QI Yanyan(Department of Internal Medicine of Staff Hospital of Zhengzhou Zhenggong Machinery Group Co.,Ltd.,Zhengzhou 450000 Henan,China)

机构地区：[1]郑州郑工机械集团有限责任公司职工医院内科,河南郑州450000

出　　处：《中国民康医学》2025年第5期31-34,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片、呋塞米注射液治疗慢性心力衰竭患者的效果。方法:选取2021年6月至2023年12月该院收治的102例慢性心力衰竭患者进行前瞻性研究,按照随机数字表法分为研究组与对照组各51例。对照组采用盐酸贝那普利片、琥珀酸美托洛尔缓释片、呋塞米注射液治疗;研究组采用沙库巴曲缬沙坦钠片、琥珀酸美托洛尔缓释片、呋塞米注射液治疗,比较两组临床疗效、心功能指标[左心室收缩末期容积指数(LVESVI)、左心室舒张末期容积指数(LVEDVI)、左心室舒张早晚期充盈速度比(E/A)、左心室射血分数(LVEF)]水平、心肌损伤指标[肌钙蛋白T、肌酸激酶同工酶(CK-MB)、N末端B型利钠肽原(NT-proBNP)和血管紧张素Ⅱ]水平、炎性指标[C反应蛋白(CRP)、降钙素原]水平和不良反应发生率。结果:研究组治疗总有效率为94.12%,明显高于对照组的74.51%,差异有统计学意义(P<0.05);治疗后,两组LVEF、E/A水平高于治疗前,且研究组高于对照组,两组LVESVI、LVEDVI、血管紧张素Ⅱ、肌钙蛋白T、CK-MB、NT-proBNP、CRP和降钙素原水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片、呋塞米注射液治疗慢性心力衰竭患者可提高治疗总有效率,改善心功能指标水平,降低心肌损伤指标和炎性指标水平,效果优于盐酸贝那普利片联合琥珀酸美托洛尔缓释片、呋塞米注射液治疗。Objective:To observe effects of Sacubitril Valsartan sodium tablets combined with Metoprolol succinate sustained-release tablets and Furosemide injection in treatment of patients with chronic heart failure.Methods:A prospective study was conducted on 102 patients with chronic heart failure admitted to this hospital from June 2021 to December 2023.According to the random number table method,they were divided into study group and control group,51 cases in each group.The control group was treated with Benazepril hydrochloride tablets,Metoprolol succinate sustained-release tablets and Furosemide injection,while the study group was treated with Sacubitril Valsartan sodium tablets,Metoprolol succinate sustained-release tablets and Furosemide injection.The clinical efficacy,the levels of cardiac function indexes [left ventricular end-systolic volume index(LVESVI),left ventricular end-diastolic volume index(LVEDVI),left ventricular early and late diastolic filling velocity ratio(E/A),left ventricular ejection fraction(LVEF)],myocardial injury indexes [troponin T,creatine kinase isoenzyme(CK-MB),N-terminal B-type natriuretic peptide(NT-proBNP) and angiotensin II] and inflammatory indexes [C-reactive protein(CRP),procalcitonin],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 94.12%,which was significantly higher than 74.51%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LVEF and E/A in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the levels of LVESVI,LVEDVI,angiotensin II,troponin T,CK-MB,NT-proBNP,CRP and procalcitonin in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions bet

关 键 词：沙库巴曲缬沙坦钠片 琥珀酸美托洛尔缓释片 呋塞米注射液 盐酸贝那普利片 慢性心力衰竭 心功能 心肌损伤 

分 类 号：R541.6[医药卫生—心血管疾病]